Diagnostic, prognostic and therapeutic role of B-type natriuretic peptide in heart failure;Kalp yetersi̇zli̇ǧi̇ tani, tedavi̇ ve prognozunun beli̇rlenmesi̇nde B-ti̇pi̇ natri̇üreti̇k pepti̇di̇n yeri̇

Turk Kardiyoloji Dernegi Arsivi

Volumn 31, Issue 8, 2003, Pages 458-465

  Çam, Neşe ^a,b   Vural, Mutlu ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Göztepe Istasyon ^*  (Turkey)

Author keywords

B type natriuretic peptide; Heart failure; Nesiritide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NESIRITIDE;

CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE SEVERITY; DIURETIC ACTIVITY; DYSPNEA; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART VENTRICLE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HIGH RISK POPULATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MORBIDITY; MORTALITY; PREDICTION; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SCREENING TEST; VASCULAR DISEASE; VASODILATATION;

EID: 0042427750     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Drumholtz HM, Chen Yt, Wan Y, et al: Predictors of readmission among elderly survivors of admission for heart failure. Am Heart J 2000;139:72-7
2. Onat A, Keleş İ, Çetinkaya A ve ark: On yillik TEKHARF Çalişmasi verilerine göre Türk erişkinlerinde koroner kökenli ölüm ve olaylarin prevelansi yüksek. Türk Kardiyol Dern Arş 2001;29:8-19
3. Taemura G, Fujifara H, Horike K, et al: Ventricular expression of atrial natriuretic polypeptide and its relations with the hemodynamics and histology in dilated human hearts. Circulation 1989;80:1137-47
4. Maeda K, Tsutamota T, Wada A, Hisanaga T, Kinoshita M: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end diastolic pressure in patient with symptomatic heart failure. Am Heart J 1998;135:825-32
5. Davidson NC, Barr CS, Struthers AD: C-type natriuretic peptide. Circulation 1996;59:1155-9
6. Stein BC, Levine RI. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ishemic heart disease. Am Heart J 1998;135:914-23
7. Nagagawa O, Ogawa Y, Itoh H, et al: Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: Evidence of BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-7
8. Sudoh T, Maekawa K, Kojima M, et al: Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophy Res Commun 1989;159:1427-34
9. McDonagh TA, Morrison CE, Lawrence A, et al: Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33
10. Francis GS, Benedict C, Johnstone DE, et al: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-9
11. Peacock WF. The B-type natriuretic peptide assay: A rapid test for heart failure. Cleve Clin J Med 2002;69:243-51
12. Kaan J, Hope J, Garcia A, et al: A rapid bedside test for brain natriuretic peptide accurately predicts cardiac function in patients referred for echocardiography. J Am Coll Cardiol 2000;135:419A
13. Redfield MR, Mahoney DW, Jacobsen SJ, et al: Isolated diastolic dysfunction in the community. Circulation 1999;Suppl:I-381
14. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clinics 2001;19:557-71
15. Yamamoto K, Bunett JC, Jougasaki M, et al: Superiority of brain natriuretic peptide is related to diastolic dysfunction in hypertension. Clin Exp Pharmacol Physiol 1997;24A: 966-8
16. Tanaka T, Hasegawa K, Fujita M, et al: Marked elevation of brain natriuretic peptide levels in pericardial fluid is closely associated with left ventricular dysfunction. J Am Coll Cardiol 1998;31:399-403
17. Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of heart failure. Eur Heart J 2001;22:1527-60
18. ACC/AHA Guidelines for the evaluation and management of chronic heart failure. J Am Coll Cardiol 2001;38:2101-13
19. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-82
20. Sayama H, Nakamura Y, Sito N, Kinoshita M: Why is the concentration of plasma brain natriuretic peptide in elderly patients is greater than normal? Coron Art Dis 1999;10:537-40
21. Tsutamoto T, Wada A, Maeda K, et al: Attenuation of compansation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patient with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16
22. Del Carlo CH, O'connor CM: Cardiac troponins in congestive heart failure. Am Heart J 1999;138:646-53
23. Setsuta K, Seino Y, Takahashi N, et al: Clinical significance of elevated levels of cardiac troponin T in patients with congestive heart failure. Am J Cardiol 1999;84:608-11
24. Ishii J, Nomura M, Nakamura Y, et al: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89:691-5
25. Cheng BS, Kazanagra R, Garcia A, et al: A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patient admitted for decompansated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91
26. Harrison A, Morrison LK, Krishnaswamy P, et al: B-type natriuretic peptide predicts future events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8
27. Tsutamoto T, Wada A, Maeda K, et al: Effect of spiranolactone on plasma brain natriuretic peptide and left ventricular remodelling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33
28. Stanek B, Frey B, Hülsmann M, et al: Prognostic evaluation of neurohormonal plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-42
29. Maeda K, Tsutamoto T, Wada A, et al: High levels of plasma natriuretic peptide and interleukin 6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93
30. Troughton RW, Framton CM, Yandle TG, et al: Treatment of heart failure guided by plasma N-terminal brain natriüretic peptide(N-BNP)concentrations. Lancet 2000;4 355:1126-30
31. Richards AM, Doughty R, Nicholls MG, et al: Neurohumoral predictors of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999;99:786-92
32. Johnson W, Omland T, Hall C, et al: Neurohumoral activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002;39:1623-9
33. Kazanegra R, Van Cheng BS, Garcia A, et al: A rapid test for B-type natriuretic peptide correlates with falling wedge pressure in patients treated for decompansated heart failure: A pilot study. J Cardiac Fail 2001;7:21-9
34. Yandle TG: Biochemistry of natriuretic peptides. J Int Med 1994;235:561-76
35. Roger MM, Lejemtel TH, Horton DP, et al: Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. J Am Coll Cardiol 1999;34:155-62
36. Wong SK, Garbers DL: Receptor guanyl cyclase. J Clin Invest 1992;90:299-305
37. Stevenson LW, Brunken RC, Belil D, et al: Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol 1990;15:174-80
38. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC: Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000;36:1706-12
39. Chen HH, Lainchbury JG, Harty GJ, Burnett JC: Maximizing the natriuretic peptide system in experimental heart failure. Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002;105:999-1003
40. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003;63:47-70
41. Burger AJ, Horton DP, LeJemtel T, et al: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8